Prevalence, Perception and Predictors of Concomitant Herbal Medicine Use among HIV/AIDS and Tuberculosis Patients in Metekel Zone, Northwest Ethiopia: A Cross-Sectional Study

Table 2

Clinical characteristics of HIV/AIDS patient study participants, Metekel zone, northwest Ethiopia (N = 355).

Variable		Frequency (%)
Know HIV status	≤5 years	141 (39.7)
	5–10 years	131 (36.9)
	10+ years	83 (23.4)
ART duration	≤5 years	148 (41.7)
	5–10 years	138 (38.9)
	10+ years	69 (19.4)
ART regimens	TDF/3TC/DTG	193 (54.4)
	TDF/3TC/EFV	136 (38.3)
	AZT/3TC/NVP	6 (1.7)
	AZT/3TC/ATV/r	20 (5.6)
Current CD4 count	≤350	86 (24.2)
	350+	269 (75.8)
Comorbidity	Yes	70 (19.7)
	No	285 (80.3)
Use of other medication	Yes	108 (30.4)
	No	247 (69.6)
Experiencing OIs	Yes	66 (18.6)
	No	289 (81.4)
Developed ART side effects	Yes	22 (6.2)
	No	333 (93.8)
History of drug discontinuation	Yes	54 (15.2)
	No	30 (14.8)

HIV: human immunodeficiency virus, TB: tuberculosis, ART: antiretroviral therapy, TDF: tenofovir disoproxil fumarate, 3TC: lamivudine, DTG: dolutegravir, AZT: zidovudine, EFV: efavirenz, and NVP: nevirapine.